메뉴 건너뛰기




Volumn 21, Issue 2, 2008, Pages 146-158

A review of the cardiovascular effects of oncology agents

Author keywords

Antineoplastic agents; Arrhythmia; Congestive heart failure; Dyslipidemia; Hypertension

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BEVACIZUMAB; BEXAROTENE; CALCIUM CHANNEL BLOCKING AGENT; CISPLATIN; DAUNORUBICIN; DIGOXIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FENOFIBRATE; FLUOROURACIL; GEMFIBROZIL; IDARUBICIN; IMATINIB; NITRATE; PACLITAXEL; RAZOXANE; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; UNINDEXED DRUG; VERAPAMIL; VORINOSTAT;

EID: 44349097993     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190008314776     Document Type: Review
Times cited : (6)

References (96)
  • 1
    • 33644868473 scopus 로고    scopus 로고
    • Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age
    • Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation. 2006 ; 113: 791-798.
    • (2006) Circulation , vol.113 , pp. 791-798
    • Lloyd-Jones, D.M.1    Leip, E.P.2    Larson, M.G.3
  • 2
    • 0003964363 scopus 로고    scopus 로고
    • Atlanta, GA: American Cancer Society;
    • Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society ; 2007.
    • (2007) Cancer Facts & Figures
  • 3
    • 43049085201 scopus 로고    scopus 로고
    • Blood pressure rise following angiogenesis inhibition by bevacizumab. a crucial role for microcirculation
    • Mourad JJ, des Guetz G., Debbabi H., Levy BI Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation. Ann Oncol. 2007 :doi:10.1093/annonc/mdm550.
    • (2007) Ann Oncol
    • Mourad, J.J.1    Des Guetz, G.2    Debbabi, H.3    Levy, B.I.4
  • 4
    • 33645449812 scopus 로고    scopus 로고
    • Mechanisms of hypertension associated with BAY 43-9006 [see comment]
    • Veronese ML, Mosenkis A., Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006 [see comment]. J Clin Oncol. 2006 ; 24: 1363-1369.
    • (2006) J Clin Oncol , vol.24 , pp. 1363-1369
    • Veronese, M.L.1    Mosenkis, A.2    Flaherty, K.T.3
  • 5
    • 0037839911 scopus 로고    scopus 로고
    • Spatial heterogeneity in VEGF-induced vasodilation: VEGF dilates microvessels but not epicardial and systemic arteries and veins
    • Laham RJ, Li J., Tofukuji M., Post M., Simons M., Sellke FW Spatial heterogeneity in VEGF-induced vasodilation: VEGF dilates microvessels but not epicardial and systemic arteries and veins. Ann Vasc Surg. 2003 ; 17: 245-252.
    • (2003) Ann Vasc Surg , vol.17 , pp. 245-252
    • Laham, R.J.1    Li, J.2    Tofukuji, M.3    Post, M.4    Simons, M.5    Sellke, F.W.6
  • 6
    • 33845490014 scopus 로고    scopus 로고
    • Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
    • Sandler A., Gray R., Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 ; 355: 2542-2550.
    • (2006) N Engl J Med , vol.355 , pp. 2542-2550
    • Sandler, A.1    Gray, R.2    Perry, M.C.3
  • 7
    • 2542561964 scopus 로고    scopus 로고
    • Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [see comment]
    • Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [see comment]. N Engl J Med. 2004 ; 350: 2335-2342.
    • (2004) N Engl J Med , vol.350 , pp. 2335-2342
    • Hurwitz, H.1    Fehrenbacher, L.2    Novotny, W.3
  • 8
    • 33846638744 scopus 로고    scopus 로고
    • Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: Systematic review and meta-analysis
    • Zhu X., Wu S., Dahut WL, Parikh CR Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis. 2007 ; 49: 186-193.
    • (2007) Am J Kidney Dis , vol.49 , pp. 186-193
    • Zhu, X.1    Wu, S.2    Dahut, W.L.3    Parikh, C.R.4
  • 9
    • 33846148701 scopus 로고    scopus 로고
    • Sorafenib in advanced clear-cell renal-cell carcinoma [see comment]
    • Escudier B., Eisen T., Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma [see comment]. N Engl J Med. 2007 ; 356: 125-134.
    • (2007) N Engl J Med , vol.356 , pp. 125-134
    • Escudier, B.1    Eisen, T.2    Stadler, W.M.3
  • 10
    • 33744984843 scopus 로고    scopus 로고
    • Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma [see comment]
    • Ratain MJ, Eisen T., Stadler WM, et al. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma [see comment]. J Clin Oncol. 2006 ; 24: 2505-2512.
    • (2006) J Clin Oncol , vol.24 , pp. 2505-2512
    • Ratain, M.J.1    Eisen, T.2    Stadler, W.M.3
  • 11
    • 34447343347 scopus 로고    scopus 로고
    • Hypertension as a predictive factor of Sunitinib activity
    • Rixe O., Billemont B., Izzedine H. Hypertension as a predictive factor of Sunitinib activity. Ann Oncol. 2007 ; 18: 1117.
    • (2007) Ann Oncol , vol.18 , pp. 1117
    • Rixe, O.1    Billemont, B.2    Izzedine, H.3
  • 12
    • 33846181370 scopus 로고    scopus 로고
    • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [see comment]
    • Motzer RJ, Hutson TE, Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma [see comment]. N Engl J Med. 2007 ; 356: 115-124.
    • (2007) N Engl J Med , vol.356 , pp. 115-124
    • Motzer, R.J.1    Hutson, T.E.2    Tomczak, P.3
  • 13
    • 33749505836 scopus 로고    scopus 로고
    • Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial
    • Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006 ; 368: 1329-1338.
    • (2006) Lancet , vol.368 , pp. 1329-1338
    • Demetri, G.D.1    Van Oosterom, A.T.2    Garrett, C.R.3
  • 15
    • 0042343801 scopus 로고    scopus 로고
    • A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer [see comment]
    • Yang JC, Haworth L., Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer [see comment]. N Engl J Med. 2003 ; 349: 427-434.
    • (2003) N Engl J Med , vol.349 , pp. 427-434
    • Yang, J.C.1    Haworth, L.2    Sherry, R.M.3
  • 16
    • 33748895713 scopus 로고    scopus 로고
    • Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway. 2006 ASCO Annual Meeting Proceedings Part I
    • Maitland ML, Moshier K., Imperial J., et al. Blood pressure (BP) as a biomarker for sorafenib (S), an inhibitor of the vascular endothelial growth factor (VEGF) signaling pathway. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol. 2006 ; 24 (June 20 suppl): 2035.
    • (2006) J Clin Oncol. , vol.24 , pp. 2035
    • Maitland, M.L.1    Moshier, K.2    Imperial, J.3
  • 17
    • 0347423198 scopus 로고    scopus 로고
    • Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure
    • Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 ; 42: 1206-1252.
    • (2003) Hypertension , vol.42 , pp. 1206-1252
    • Chobanian, A.V.1    Bakris, G.L.2    Black, H.R.3
  • 18
    • 33749251592 scopus 로고    scopus 로고
    • Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab
    • Azad NS, Posadas EM, Kwitkowski VE, et al. Increased efficacy and toxicity with combination anti-VEGF therapy using sorafenib and bevacizumab. J Clin Oncol (Meeting Abstracts). 2006 ; 24 (18 _suppl). 3004.
    • (2006) J Clin Oncol (Meeting Abstracts) , vol.24 , Issue.18 , pp. 3004
    • Azad, N.S.1    Posadas, E.M.2    Kwitkowski, V.E.3
  • 19
    • 44349148825 scopus 로고    scopus 로고
    • Dual targeting of vascular endothelial growth factor (VEGF) with sorafenib and bevacizumab: Clinical and translational results
    • Azad NS, Annunziata C., Barrett T., et al. Dual targeting of vascular endothelial growth factor (VEGF) with sorafenib and bevacizumab: clinical and translational results. J Clin Oncol (Meeting Abstracts). 2007 ; 25 (18 _suppl). 3542.
    • (2007) J Clin Oncol (Meeting Abstracts) , vol.25 , Issue.18 , pp. 3542
    • Azad, N.S.1    Annunziata, C.2    Barrett, T.3
  • 20
    • 35548945707 scopus 로고    scopus 로고
    • Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC)
    • Feldman DR, Kondagunta GV, Ronnen EA, et al. Phase I trial of bevacizumab plus sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol (Meeting Abstracts). 2007 ; 25 (18 _suppl). 5099.
    • (2007) J Clin Oncol (Meeting Abstracts) , vol.25 , Issue.18 , pp. 5099
    • Feldman, D.R.1    Kondagunta, G.V.2    Ronnen, E.A.3
  • 21
    • 37149006085 scopus 로고    scopus 로고
    • A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors
    • Cooney MM, Garcia J., Brell J., et al. A phase I study of bevacizumab in combination with sunitinib in advanced solid tumors. J Clin Oncol (Meeting Abstracts). 2007 ; 25 (18 _suppl). 15532.
    • (2007) J Clin Oncol (Meeting Abstracts) , vol.25 , Issue.18 , pp. 15532
    • Cooney, M.M.1    Garcia, J.2    Brell, J.3
  • 22
    • 34447345394 scopus 로고    scopus 로고
    • Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors
    • Dirix LY, Maes H., Sweldens C. Treatment of arterial hypertension (AHT) associated with angiogenesis inhibitors. Ann Oncol. 2007 ; 18: 1121-1122.
    • (2007) Ann Oncol , vol.18 , pp. 1121-1122
    • Dirix, L.Y.1    Maes, H.2    Sweldens, C.3
  • 23
    • 34447635695 scopus 로고    scopus 로고
    • Angiogenesis inhibitor therapies: Focus on kidney toxicity and hypertension
    • Izzedine H., Rixe O., Billemont B., Baumelou A., Deray G. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis. 2007 ; 50: 203-218.
    • (2007) Am J Kidney Dis , vol.50 , pp. 203-218
    • Izzedine, H.1    Rixe, O.2    Billemont, B.3    Baumelou, A.4    Deray, G.5
  • 24
    • 0034999546 scopus 로고    scopus 로고
    • Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma [see comment]
    • Duvic M., Martin AG, Kim Y., et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma [see comment]. Arch Dermatol. 2001 ; 137: 581-593.
    • (2001) Arch Dermatol , vol.137 , pp. 581-593
    • Duvic, M.1    Martin, A.G.2    Kim, Y.3
  • 25
    • 0035340844 scopus 로고    scopus 로고
    • Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous t-cell lymphoma: Multinational phase II-III trial results
    • Duvic M., Hymes K., Heald P., et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous t-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001 ; 19: 2456-2471.
    • (2001) J Clin Oncol , vol.19 , pp. 2456-2471
    • Duvic, M.1    Hymes, K.2    Heald, P.3
  • 26
    • 33750609546 scopus 로고    scopus 로고
    • Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies
    • Govindan R., Crowley J., Schwartzberg L., et al. Phase II trial of bexarotene capsules in patients with advanced non-small-cell lung cancer after failure of two or more previous therapies. J Clin Oncol. 2006 ; 24: 4848-4854.
    • (2006) J Clin Oncol , vol.24 , pp. 4848-4854
    • Govindan, R.1    Crowley, J.2    Schwartzberg, L.3
  • 27
    • 0030902788 scopus 로고    scopus 로고
    • Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C
    • Shinohara E., Yamashita S., Kihara S., et al. Interferon alpha induces disorder of lipid metabolism by lowering postheparin lipases and cholesteryl ester transfer protein activities in patients with chronic hepatitis C. Hepatology. 1997 ; 25: 1502-1506.
    • (1997) Hepatology , vol.25 , pp. 1502-1506
    • Shinohara, E.1    Yamashita, S.2    Kihara, S.3
  • 28
    • 34249779568 scopus 로고    scopus 로고
    • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
    • Hudes G., Carducci M., Tomczak P., et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007 ; 356: 2271-2281.
    • (2007) N Engl J Med , vol.356 , pp. 2271-2281
    • Hudes, G.1    Carducci, M.2    Tomczak, P.3
  • 29
    • 0026534161 scopus 로고
    • The role of the cytokines, interferon alpha and tumor necrosis factor in the hypertriglyceridemia and wasting of AIDs
    • Grunfeld C., Feingold KR The role of the cytokines, interferon alpha and tumor necrosis factor in the hypertriglyceridemia and wasting of AIDs. J Nutr. 1992 ; 122 (3 suppl). 749-753.
    • (1992) J Nutr , vol.122 , Issue.3 , pp. 749-753
    • Grunfeld, C.1    Feingold, K.R.2
  • 30
    • 0032883745 scopus 로고    scopus 로고
    • Drug-induced hypertriglyceridemia with and without pancreatitis
    • Keung YK, Rizk R., Wu XY, Cobos E. Drug-induced hypertriglyceridemia with and without pancreatitis. South Med J. 1999 ; 92: 912-914.
    • (1999) South Med J , vol.92 , pp. 912-914
    • Keung, Y.K.1    Rizk, R.2    Wu, X.Y.3    Cobos, E.4
  • 31
    • 4644235349 scopus 로고    scopus 로고
    • Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma
    • Wong, S-F., Jakowatz JG, Taheri R. Management of hypertriglyceridemia in patients receiving interferon for malignant melanoma. Ann Pharmacother. 2004 ; 38: 1655-1659.
    • (2004) Ann Pharmacother , vol.38 , pp. 1655-1659
    • Wong, S.-F.1    Jakowatz, J.G.2    Taheri, R.3
  • 32
    • 0344959456 scopus 로고    scopus 로고
    • Lipoprotein changes in patients with chronic hepatitis C treated with interferon-alpha
    • Fernandez-Miranda C., Castellano G., Guijarro C., et al. Lipoprotein changes in patients with chronic hepatitis C treated with interferon-alpha. Am J Gastroenterol. 1998 ; 93: 1901-1904.
    • (1998) Am J Gastroenterol , vol.93 , pp. 1901-1904
    • Fernandez-Miranda, C.1    Castellano, G.2    Guijarro, C.3
  • 33
    • 0027451466 scopus 로고
    • Severe hypertriglyceridaemia and interferon-alpha
    • Sunderkotter C., Luger T., Kolde G. Severe hypertriglyceridaemia and interferon-alpha. Lancet. 1993 ; 342: 1111-1112.
    • (1993) Lancet , vol.342 , pp. 1111-1112
    • Sunderkotter, C.1    Luger, T.2    Kolde, G.3
  • 34
    • 0034235806 scopus 로고    scopus 로고
    • Acute pancreatitis attributed to the use of interferon alfa-2b
    • Eland IA, Rasch MC, Sturkenboom MJ, et al. Acute pancreatitis attributed to the use of interferon alfa-2b. Gastroenterology. 2000 ; 119: 230-233.
    • (2000) Gastroenterology , vol.119 , pp. 230-233
    • Eland, I.A.1    Rasch, M.C.2    Sturkenboom, M.J.3
  • 35
    • 44349136992 scopus 로고    scopus 로고
    • Distinct mechanisms by which low and high rapamycin doses raise plasma triglycerides in guinea pigs
    • Aggarwal D., Fernandez, ML, Soliman GA Distinct mechanisms by which low and high rapamycin doses raise plasma triglycerides in guinea pigs. FASEB J. 2006 ; 20: A136-a.
    • (2006) FASEB J , vol.20
    • Aggarwal, D.1    Fernandez, M.L.2    Soliman, G.A.3
  • 36
    • 0037126526 scopus 로고    scopus 로고
    • Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report
    • Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report. Circulation. 2002 ; 106: 3143-3142.
    • (2002) Circulation , vol.106 , pp. 3143-3142
  • 38
    • 33745913350 scopus 로고    scopus 로고
    • Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: An expert opinion
    • Assaf C., Bagot M., Dummer R., et al. Minimizing adverse side-effects of oral bexarotene in cutaneous T-cell lymphoma: an expert opinion. Br J Dermatol. 2006 ; 155: 261-266.
    • (2006) Br J Dermatol , vol.155 , pp. 261-266
    • Assaf, C.1    Bagot, M.2    Dummer, R.3
  • 39
    • 3042623891 scopus 로고    scopus 로고
    • Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy [see comment]
    • Chang JT, Staffa JA, Parks M., Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy [see comment]. Pharmacoepidemiology & Drug Safety. 2004 ; 13: 417-426.
    • (2004) Pharmacoepidemiology & Drug Safety , vol.13 , pp. 417-426
    • Chang, J.T.1    Staffa, J.A.2    Parks, M.3    Green, L.4
  • 40
    • 2642566088 scopus 로고    scopus 로고
    • Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity
    • Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004 ; 56: 185-229.
    • (2004) Pharmacol Rev , vol.56 , pp. 185-229
    • Minotti, G.1    Menna, P.2    Salvatorelli, E.3    Cairo, G.4    Gianni, L.5
  • 41
    • 0014066067 scopus 로고
    • Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia
    • Tan C., Tasaka H., Yu KP, Murphy ML, Karnofsky DA Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer. 1967 ; 20: 333-353.
    • (1967) Cancer , vol.20 , pp. 333-353
    • Tan, C.1    Tasaka, H.2    Kp, Y.3    Murphy, M.L.4    Karnofsky, D.A.5
  • 42
    • 33745008604 scopus 로고    scopus 로고
    • Pathogenesis of cardiotoxicity induced by anthracyclines
    • Elliott P. Pathogenesis of cardiotoxicity induced by anthracyclines. Semin Oncol. 2006 ; 33 (3 suppl 8). S2 - S7.
    • (2006) Semin Oncol , vol.33 , Issue.3-8
    • Elliott, P.1
  • 43
    • 0015849162 scopus 로고
    • A clinicopathologic analysis of adriamycin cardiotoxicity
    • Lefrak EA, Pitha J., Rosenheim S., Gottlieb JA A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer. 1973 ; 32: 302-314.
    • (1973) Cancer , vol.32 , pp. 302-314
    • Lefrak, E.A.1    Pitha, J.2    Rosenheim, S.3    Gottlieb, J.A.4
  • 44
    • 0018716636 scopus 로고
    • Risk factors for doxorubicin-induced congestive heart failure
    • Von Hoff DD, Layard MW, Basa P., et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med. 1979 ; 91: 710-717.
    • (1979) Ann Intern Med , vol.91 , pp. 710-717
    • Von Hoff, D.D.1    Layard, M.W.2    Basa, P.3
  • 46
    • 0033813886 scopus 로고    scopus 로고
    • Molecular basis of anthracycline-induced cardiotoxicity and its prevention
    • Horenstein MS, Vander Heide RS, L'Ecuyer TJ Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab. 2000 ; 71: 436-444.
    • (2000) Mol Genet Metab , vol.71 , pp. 436-444
    • Horenstein, M.S.1    Vander Heide, R.S.2    L'Ecuyer, T.J.3
  • 47
    • 33745006819 scopus 로고    scopus 로고
    • Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer
    • Jensen BV Cardiotoxic consequences of anthracycline-containing therapy in patients with breast cancer. Semin Oncol. 2006 ; 33 (3 suppl 8). S15 - S21.
    • (2006) Semin Oncol , vol.33 , Issue.3-8
    • Jensen, B.V.1
  • 48
    • 0037293503 scopus 로고    scopus 로고
    • Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma
    • Limat S., Demesmay K., Voillat L., et al. Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol. 2003 ; 14: 277-281.
    • (2003) Ann Oncol , vol.14 , pp. 277-281
    • Limat, S.1    Demesmay, K.2    Voillat, L.3
  • 50
    • 0025850827 scopus 로고
    • Cardiac toxicity 4 to 20 years after completing anthracycline therapy
    • Steinherz LJ, Steinherz PG, Tan CT, Heller G., Murphy ML Cardiac toxicity 4 to 20 years after completing anthracycline therapy. JAMA. 1991 ; 266: 1672-1677.
    • (1991) JAMA , vol.266 , pp. 1672-1677
    • Steinherz, L.J.1    Steinherz, P.G.2    Tan, C.T.3    Heller, G.4    Murphy, M.L.5
  • 51
    • 34548509227 scopus 로고    scopus 로고
    • Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors
    • Hudson MM, Rai SN, Nunez C., et al. Noninvasive evaluation of late anthracycline cardiac toxicity in childhood cancer survivors. J Clin Oncol. 2007 ; 25: 3635-3643.
    • (2007) J Clin Oncol , vol.25 , pp. 3635-3643
    • Hudson, M.M.1    Rai, S.N.2    Nunez, C.3
  • 52
    • 0031801499 scopus 로고    scopus 로고
    • Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas
    • Haddy TB, Adde MA, McCalla J., et al. Late effects in long-term survivors of high-grade non-Hodgkin's lymphomas. J Clin Oncol. 1998 ; 16: 2070-2079.
    • (1998) J Clin Oncol , vol.16 , pp. 2070-2079
    • Haddy, T.B.1    Ma, A.2    McCalla, J.3
  • 53
    • 0035155497 scopus 로고    scopus 로고
    • Anthracycline-induced clinical heart failure in a cohort of 607 children: Long-term follow-up study
    • Kremer LC, van Dalen EC, Offringa M., Ottenkamp J., Voute PA Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol. 2001 ; 19: 191-196.
    • (2001) J Clin Oncol , vol.19 , pp. 191-196
    • Kremer, L.C.1    Van Dalen, E.C.2    Offringa, M.3    Ottenkamp, J.4    Voute, P.A.5
  • 54
    • 32244434654 scopus 로고    scopus 로고
    • Anticancer agents and cardiotoxicity
    • Ng R., Better N., Green MD Anticancer agents and cardiotoxicity. Semin Oncol. 2006 ; 33: 2-14.
    • (2006) Semin Oncol , vol.33 , pp. 2-14
    • Ng, R.1    Better, N.2    Green, M.D.3
  • 55
    • 0018134347 scopus 로고
    • Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals
    • Friedman MA, Bozdech MJ, Billingham ME, Rider AK Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. JAMA. 1978 ; 240: 1603-1606.
    • (1978) JAMA , vol.240 , pp. 1603-1606
    • Ma, F.1    Bozdech, M.J.2    Billingham, M.E.3    Rider, A.K.4
  • 56
    • 0020700877 scopus 로고
    • Clinical and morphologic cardiac findings after anthracycline chemotherapy: Analysis of 64 patients studied at necropsy
    • Isner JM, Ferrans VJ, Cohen SR, et al. Clinical and morphologic cardiac findings after anthracycline chemotherapy: analysis of 64 patients studied at necropsy. Am J Cardiol. 1983 ; 51: 1167-1174.
    • (1983) Am J Cardiol , vol.51 , pp. 1167-1174
    • Isner, J.M.1    Ferrans, V.J.2    Cohen, S.R.3
  • 59
    • 0021833736 scopus 로고
    • A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer
    • Jain KK, Casper ES, Geller NL, et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol. 1985 ; 3: 818-826.
    • (1985) J Clin Oncol , vol.3 , pp. 818-826
    • Jain, K.K.1    Casper, E.S.2    Geller, N.L.3
  • 60
    • 0035282073 scopus 로고    scopus 로고
    • Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer [see comment]
    • Batist G., Ramakrishnan G., Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer [see comment]. J Clin Oncol. 2001 ; 19: 1444-1454.
    • (2001) J Clin Oncol , vol.19 , pp. 1444-1454
    • Batist, G.1    Ramakrishnan, G.2    Rao, C.S.3
  • 61
    • 0036142158 scopus 로고    scopus 로고
    • Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma
    • Harris L., Batist G., Belt R., et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002 ; 94: 25-36.
    • (2002) Cancer , vol.94 , pp. 25-36
    • Harris, L.1    Batist, G.2    Belt, R.3
  • 62
    • 0033168435 scopus 로고    scopus 로고
    • Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes
    • Symon Z., Peyser A., Tzemach D., et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer. 1999 ; 86: 72-78.
    • (1999) Cancer , vol.86 , pp. 72-78
    • Symon, Z.1    Peyser, A.2    Tzemach, D.3
  • 64
    • 0027409325 scopus 로고
    • Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit
    • Cusack BJ, Young SP, Driskell J., Olson RD Doxorubicin and doxorubicinol pharmacokinetics and tissue concentrations following bolus injection and continuous infusion of doxorubicin in the rabbit. Cancer Chemother Pharmacol. 1993 ; 32: 53-58.
    • (1993) Cancer Chemother Pharmacol , vol.32 , pp. 53-58
    • Cusack, B.J.1    Young, S.P.2    Driskell, J.3    Olson, R.D.4
  • 65
    • 0021355628 scopus 로고
    • Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: A prospective, randomized study
    • Valdivieso M., Burgess MA, Ewer MS, et al. Increased therapeutic index of weekly doxorubicin in the therapy of non-small cell lung cancer: a prospective, randomized study. J Clin Oncol. 1984 ; 2: 207-214.
    • (1984) J Clin Oncol , vol.2 , pp. 207-214
    • Valdivieso, M.1    Ma, B.2    Ewer, M.S.3
  • 66
    • 0024431933 scopus 로고
    • Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer
    • Umsawasdi T., Valdivieso M., Booser DJ, et al. Weekly doxorubicin versus doxorubicin every 3 weeks in cyclophosphamide, doxorubicin, and cisplatin chemotherapy for non-small cell lung cancer. Cancer. 1989 ; 64: 1995-2000.
    • (1989) Cancer , vol.64 , pp. 1995-2000
    • Umsawasdi, T.1    Valdivieso, M.2    Booser, D.J.3
  • 67
    • 0021063443 scopus 로고
    • Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule
    • Torti FM, Bristow MR, Howes AE, et al. Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Ann Intern Med. 1983 ; 99: 745.
    • (1983) Ann Intern Med , vol.99 , pp. 745
    • Torti, F.M.1    Bristow, M.R.2    Howes, A.E.3
  • 68
    • 0017199039 scopus 로고
    • Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity
    • Weiss AJ, Metter GE, Fletcher WS, Wilson WL, Grage TB, Ramirez G. Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep. 1976 ; 60: 813-822.
    • (1976) Cancer Treat Rep , vol.60 , pp. 813-822
    • Weiss, A.J.1    Metter, G.E.2    Fletcher, W.S.3    Wilson, W.L.4    Grage, T.B.5    Ramirez, G.6
  • 69
    • 42749107115 scopus 로고    scopus 로고
    • Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy
    • van Dalen EC, van der Pal HJ, Caron HN, Kremer LC Different dosage schedules for reducing cardiotoxicity in cancer patients receiving anthracycline chemotherapy. Cochrane Database Syst Rev. 2006: CD005008.
    • (2006) Cochrane Database Syst Rev , pp. 005008
    • Van Dalen, E.C.1    Van Der Pal, H.J.2    Caron, H.N.3    Kremer, L.C.4
  • 70
    • 34248573600 scopus 로고    scopus 로고
    • Managing cardiotoxicity in anthracycline-treated breast cancers
    • Ng R., Green MD Managing cardiotoxicity in anthracycline-treated breast cancers. Expert Opin Drug Saf. 2007 ; 6: 315-321.
    • (2007) Expert Opin Drug Saf , vol.6 , pp. 315-321
    • Ng, R.1    Green, M.D.2
  • 71
    • 0030904096 scopus 로고    scopus 로고
    • Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer
    • Swain SM, Whaley FS, Gerber MC, et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J Clin Oncol. 1997 ; 15: 1318-1332.
    • (1997) J Clin Oncol , vol.15 , pp. 1318-1332
    • Swain, S.M.1    Whaley, F.S.2    Gerber, M.C.3
  • 72
    • 0037096826 scopus 로고    scopus 로고
    • Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology
    • Schuchter LM, Hensley ML, Meropol NJ, Winer EP 2002 Update of Recommendations for the Use of Chemotherapy and Radiotherapy Protectants: Clinical Practice Guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2002 ; 20: 2895-2903.
    • (2002) J Clin Oncol , vol.2002 , Issue.20 , pp. 2895-2903
    • Schuchter, L.M.1    Hensley, M.L.2    Meropol, N.J.3    Winer, E.P.4
  • 73
    • 0034872172 scopus 로고    scopus 로고
    • Tolerability in patients receiving trastuzumab with or without chemotherapy
    • Gianni L. Tolerability in patients receiving trastuzumab with or without chemotherapy. Ann Oncol. 2001 ; 12 (suppl 1). S63 - S68.
    • (2001) Ann Oncol , vol.12 , Issue.1
    • Gianni, L.1
  • 75
    • 0036498781 scopus 로고    scopus 로고
    • Cardiac dysfunction in the trastuzumab clinical trials experience [see comment]
    • Seidman A., Hudis C., Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience [see comment]. J Clin Oncol. 2002 ; 20: 1215-1221.
    • (2002) J Clin Oncol , vol.20 , pp. 1215-1221
    • Seidman, A.1    Hudis, C.2    Pierri, M.K.3
  • 76
    • 0035257549 scopus 로고    scopus 로고
    • Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials
    • Slamon D., Pegram M. Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Semin Oncol. 2001 ; 28 (1 suppl 3). 13-19.
    • (2001) Semin Oncol , vol.28 , Issue.1-3 , pp. 13-19
    • Slamon, D.1    Pegram, M.2
  • 77
    • 34548152541 scopus 로고    scopus 로고
    • Trastuzumab-related cardiotoxicity: Calling into question the concept of reversibility
    • Telli ML, Hunt SA, Carlson RW, GuardinoAE Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol. 2007 ; 25: 3525-3533.
    • (2007) J Clin Oncol , vol.25 , pp. 3525-3533
    • Telli, M.L.1    Hunt, S.A.2    Carlson, R.W.3    Guardinoae4
  • 78
    • 34247480545 scopus 로고    scopus 로고
    • Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition
    • Force T., Krause DS, Van Etten RA Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007 ; 7: 332-344.
    • (2007) Nat Rev Cancer , vol.7 , pp. 332-344
    • Force, T.1    Krause, D.S.2    Van Etten, R.A.3
  • 79
    • 23944476155 scopus 로고    scopus 로고
    • Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas
    • Burris HA III, Hurwitz HI, Dees EC, et al. Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J Clin Oncol. 2005 ; 23: 5305-5313.
    • (2005) J Clin Oncol , vol.23 , pp. 5305-5313
    • Burris III, H.A.1    Hurwitz, H.I.2    Dees, E.C.3
  • 80
    • 33845886440 scopus 로고    scopus 로고
    • Lapatinib plus capecitabine for HER2-positive advanced breast cancer [see comment]
    • Geyer CE, Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer [see comment]. N Engl J Med. 2006 ; 355: 2733-2743.
    • (2006) N Engl J Med , vol.355 , pp. 2733-2743
    • Geyer, C.E.1    Forster, J.2    Lindquist, D.3
  • 81
    • 0032563825 scopus 로고    scopus 로고
    • Doxorubicin-induced cardiomyopathy [see comment]
    • Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy [see comment]. N Engl J Med. 1998 ; 339: 900-905.
    • (1998) N Engl J Med , vol.339 , pp. 900-905
    • Singal, P.K.1    Iliskovic, N.2
  • 82
    • 33744976073 scopus 로고    scopus 로고
    • Exposure to anthracyclines during childhood causes cardiac injury
    • Lipshultz SE Exposure to anthracyclines during childhood causes cardiac injury. Semin Oncol. 2006 ; 33 (3 suppl 8). S8 - S14.
    • (2006) Semin Oncol , vol.33 , Issue.3-8
    • Lipshultz, S.E.1
  • 83
    • 1542608355 scopus 로고    scopus 로고
    • Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines
    • Silber JH, Cnaan A., Clark BJ, et al. Enalapril to prevent cardiac function decline in long-term survivors of pediatric cancer exposed to anthracyclines. J Clin Oncol. 2004 ; 22: 820-828.
    • (2004) J Clin Oncol , vol.22 , pp. 820-828
    • Silber, J.H.1    Cnaan, A.2    Clark, B.J.3
  • 84
    • 0036938433 scopus 로고    scopus 로고
    • Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia
    • Thomas, Thomas X, Le, Le Q, Fiere, Fiere D. Anthracycline-related toxicity requiring cardiac transplantation in long-term disease-free survivors with acute promyelocytic leukemia. Ann Hematol. 2002 ; 81: 504-507.
    • (2002) Ann Hematol , vol.81 , pp. 504-507
    • Thomas Thomas, X.1    Le Le, Q.2    Fiere Fiere, D.3
  • 86
    • 0035884639 scopus 로고    scopus 로고
    • United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia
    • Soignet SL, Frankel SR, Douer D., et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001 ; 19: 3852-3860.
    • (2001) J Clin Oncol , vol.19 , pp. 3852-3860
    • Soignet, S.L.1    Frankel, S.R.2    Douer, D.3
  • 87
    • 34548319126 scopus 로고    scopus 로고
    • Pathophysiology and diagnosis of cancer drug induced cardiomyopathy
    • Zuppinger C., Timolati F., Suter TM Pathophysiology and diagnosis of cancer drug induced cardiomyopathy. Cardiovasc Toxicol. 2007 ; 7: 61-66.
    • (2007) Cardiovasc Toxicol , vol.7 , pp. 61-66
    • Zuppinger, C.1    Timolati, F.2    Suter, T.M.3
  • 88
    • 34247580900 scopus 로고    scopus 로고
    • QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines
    • Arbel Y., Swartzon M., Justo D. QT prolongation and Torsades de Pointes in patients previously treated with anthracyclines. Anticancer Drugs. 2007 ; 18: 493-498.
    • (2007) Anticancer Drugs , vol.18 , pp. 493-498
    • Arbel, Y.1    Swartzon, M.2    Justo, D.3
  • 89
    • 0026007513 scopus 로고
    • Cisplatin-induced atrial fibrillation
    • Menard O., Martinet Y., Lamy P. Cisplatin-induced atrial fibrillation. J Clin Oncol. 1991 ; 9: 192-193.
    • (1991) J Clin Oncol , vol.9 , pp. 192-193
    • Menard, O.1    Martinet, Y.2    Lamy, P.3
  • 90
    • 0024636426 scopus 로고
    • High-frequency atrial arrhythmia induced by a cisplatin-etoposide combination [in Italian]
    • Petrella V., Alciato P., Cantone PA, Fico D., Gagliardini R. High-frequency atrial arrhythmia induced by a cisplatin-etoposide combination [in Italian]. Minerva Med. 1989 ; 80: 305-307.
    • (1989) Minerva Med , vol.80 , pp. 305-307
    • Petrella, V.1    Alciato, P.2    Cantone, P.A.3    Fico, D.4    Gagliardini, R.5
  • 91
    • 0031462142 scopus 로고    scopus 로고
    • Cardiac arrhythmias after cisplatin infusion: Three case reports and a review of the literature
    • Tassinari D., Sartori S., Drudi G., et al. Cardiac arrhythmias after cisplatin infusion: three case reports and a review of the literature. Ann Oncol. 1997 ; 8: 1263-1267.
    • (1997) Ann Oncol , vol.8 , pp. 1263-1267
    • Tassinari, D.1    Sartori, S.2    Drudi, G.3
  • 93
    • 33748458673 scopus 로고    scopus 로고
    • Severe ventricular dysrhythmias and silent ischemia during infusion of the antimetabolite 5-fluorouracil and cisplatin
    • Hrovatin E., Viel E., Lestuzzi C., et al. Severe ventricular dysrhythmias and silent ischemia during infusion of the antimetabolite 5-fluorouracil and cisplatin. J Cardiovasc Med. 2006 ; 7: 637-640.
    • (2006) J Cardiovasc Med , vol.7 , pp. 637-640
    • Hrovatin, E.1    Viel, E.2    Lestuzzi, C.3
  • 94
    • 21244464349 scopus 로고    scopus 로고
    • Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer
    • Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol. 2005 ; 23: 3923-3931.
    • (2005) J Clin Oncol , vol.23 , pp. 3923-3931
    • Kelly, W.K.1    O'Connor, O.A.2    Krug, L.M.3
  • 95
    • 19744377392 scopus 로고    scopus 로고
    • Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron [see comment]
    • Charbit B., Albaladejo P., Funck-Brentano C., Legrand M., Samain E., Marty J. Prolongation of QTc interval after postoperative nausea and vomiting treatment by droperidol or ondansetron [see comment]. Anesthesiology. 2005 ; 102: 1094-1100.
    • (2005) Anesthesiology , vol.102 , pp. 1094-1100
    • Charbit, B.1    Albaladejo, P.2    Funck-Brentano, C.3    Legrand, M.4    Samain, E.5    Marty, J.6
  • 96
    • 33748490073 scopus 로고    scopus 로고
    • Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer
    • Pinarli FG, Elli M., Dagdemir A., Baysal K., Acar S. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer. Pediatr Blood Cancer. 2006 ; 47: 567-571.
    • (2006) Pediatr Blood Cancer , vol.47 , pp. 567-571
    • Pinarli, F.G.1    Elli, M.2    Dagdemir, A.3    Baysal, K.4    Acar, S.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.